Welcome to our dedicated page for Picard Medical SEC filings (Ticker: PMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This Picard Medical, Inc. (PMI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Picard Medical is a Delaware corporation listed on the NYSE American, and its filings describe a business conducted through SynCardia Systems, LLC, a medical technology company that manufactures and sells the SynCardia Total Artificial Heart (STAH) for patients with advanced heart failure.
Through documents such as Form S-1 registration statements and Form 8-K current reports, investors can review detailed information about Picard Medical’s operations, financing arrangements, and risk factors. The S-1 filing explains that SynCardia’s platform includes the SynCardia 50cc and 70cc total artificial hearts, external drivers, ancillary hardware, and associated surgeon and center training. It also notes that the company’s customers are major medical centers operating heart transplant and mechanical circulatory support programs and that SynCardia operates an ISO 13485–certified quality management system.
Form 8-K filings for Picard Medical include disclosures on material definitive agreements, such as senior secured notes and warrant financings, bridge financing arrangements, and related security agreements. Additional 8-Ks furnish press releases and presentation materials related to clinical and technical updates on the next-generation, fully implantable Emperor Total Artificial Heart, as well as corporate events like conference presentations and exchange bell-ringing ceremonies.
On this page, users can follow real-time updates from EDGAR and use AI-powered summaries to understand the key points in lengthy filings. Forms such as the S-1, 8-K, and any future 10-K annual reports, 10-Q quarterly reports, or proxy statements can provide insight into Picard Medical’s capital structure, governance, risk profile, and the progress of its SynCardia and Emperor total artificial heart platforms. Insider transaction reports on Form 4, when available, can also be reviewed to see changes in beneficial ownership by company insiders.
Picard Medical, Inc. reported that its Engineering Project Manager, Duffy Elmer, presented in vitro data on the company’s Emperor Total Artificial Heart at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support in Vienna, Austria. The presentation highlights ongoing development work on the Emperor Total Artificial Heart, a key technology in the company’s portfolio.
The company made available an abstract of the Emperor Total Artificial Heart and the slide deck used in the presentation as exhibits to this report. These materials are furnished, not filed, which means they are provided for information purposes and are not subject to the liability provisions that apply to formal filed reports.
Picard Medical, Inc. reported that its CEO, Patrick NJ Schnegelsberg, will present data on the company’s Emperor Total Artificial Heart at the CSI Focus D-HF (Device Therapies in Heart Failure) conference. The event is scheduled for December 5 and 6, 2025, in Frankfurt, Germany, giving the company an opportunity to share clinical or technical information about its artificial heart technology with a specialized cardiovascular audience.
The update is being shared through a press release furnished as an exhibit to this current report, and is characterized as supplemental information that is not deemed filed for liability purposes under federal securities laws.
Picard Medical, Inc. entered into a short-term bridge financing on November 26, 2025 through an unsecured promissory note with Fang Family Fund, LLC, an affiliate of its Board Chairman, Richard Fang. The lender agreed to provide a principal amount of $1,000,000 at an annual interest rate of 6%, compounded annually, with all principal and accrued interest due on November 27, 2026. The company may prepay the note at any time without penalty and plans to use the funds for general corporate purposes, including working capital, liquidity management, and near-term operating expenses. The related-party transaction was reviewed and approved by disinterested members of the Audit Committee and Board, who determined the terms are fair and comparable to those available from an unaffiliated third party. The company entered into this note to address short-term liquidity needs and currently expects to repay it from operating cash flow and/or future financing or refinancing.
Picard Medical, Inc. reported that Duffy Elmer will present in vitro data on the company’s Emperor Total Artificial Heart at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support in Vienna, Austria, taking place between December 1 and 4, 2025. The announcement was made through a press release dated November 26, 2025, which is attached as an exhibit and incorporated by reference. The company also clarified that this information is being furnished, not filed, under securities laws, which limits its use in certain legal contexts.
Picard Medical, Inc. reported that its wholly owned subsidiary, SynCardia Systems LLC, has completed the first in vivo implantations of the Emperor Total Artificial Heart. This marks an important clinical milestone for the company’s artificial heart technology, moving it from development toward real-world use in living subjects.
The announcement was made through a press release furnished as an exhibit to this current report. The disclosure is informational and is stated as being furnished rather than filed under securities laws, which limits how it is incorporated into other regulatory documents.
Picard Medical, Inc. filed an 8-K stating it issued a press release announcing financial and operating results for the third quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference within this report.
The company notes the information is furnished, not filed under the Exchange Act and is not incorporated by reference into Securities Act or Exchange Act filings, despite any general incorporation language.
Picard Medical, Inc. (PMI) reported Q3 2025 results showing modest revenue growth but continued losses and a going concern warning. Quarterly revenue was $1.187 million, up from $0.881 million a year ago, with products driving most sales. Gross loss narrowed to $0.130 million from $0.673 million as product costs improved.
Operating loss was $3.487 million. Other expense rose sharply on interest and derivative impacts, leading to a net loss of $10.426 million for the quarter. For the nine months, revenue reached $3.931 million versus $3.555 million last year, with a net loss of $22.711 million.
The balance sheet shifted after the September 2, 2025 IPO and note conversions: derivative liabilities fell to $0 from $6.759 million and total liabilities dropped to $5.553 million from $35.842 million at year-end. Cash increased to $2.813 million from $0.096 million, aided by $17.4 million of net common stock proceeds and debt activity. Shares outstanding were 73,701,176 as of November 10, 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing.
Affiliates of Versa Capital, including Sindex SSI Lending, LLC, filed an initial Form 3 reporting beneficial ownership in Picard Medical, Inc. (PMI) as of 08/11/2025. The filing lists 7,943,585 shares of common stock beneficially owned and indicates the reporting person is a Director and 10% Owner. The form was filed by more than one reporting person and notes that the shares are held by Sindex, with a control chain through Versa entities and Gregory L. Segall.
Picard Medical, Inc. (PMI) received a Schedule 13G from Sindex SSI Lending, LLC, Versa Capital Fund III, L.P., related Versa entities, and Gregory L. Segall, disclosing passive beneficial ownership in the company’s common stock. The filing lists 7,943,585 shares beneficially owned, representing 10.8% of the class, tied to an outstanding base of 73,701,176 shares as of September 16, 2025. The date of event triggering the filing is August 11, 2025.
Each reporting person reports sole voting power: 7,943,585 shares and sole dispositive power: 7,943,585 shares, with no shared voting or dispositive power. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control, indicating a passive investment stance.
Picard Medical, Inc. filed a Form 8-K stating it furnished a press release discussing the volatility of its stock price. The press release is included as Exhibit 99.1 and dated October 24, 2025.
The company’s common stock trades on the NYSE American under the symbol PMI. No financial results or transactions are described in this filing.